| Literature DB >> 33050360 |
Rajveer Singh1, Anupam Gautam2,3, Shivani Chandel1, Arijit Ghosh4, Dhritiman Dey1, Syamal Roy1, Velayutham Ravichandiran1, Dipanjan Ghosh1.
Abstract
The current pandemic, caused by SARS-CoV-2 virus, is a severe challenge for human health and the world economy. There is an urgent need for development of drugs that can manage this pandemic, as it has already infected 19 million people and led to the death of around 711,277 people worldwide. At this time, in-silico studies are providing lots of preliminary data about potential drugs, which can be a great help in further in-vitro and in-vivo studies. Here, we have selected three polyphenolic compounds, mangiferin, glucogallin, and phlorizin. These compounds are isolated from different natural sources but share structural similarities and have been reported for their antiviral activity. The objective of this study is to analyze and predict the anti-protease activity of these compounds on SARS-CoV-2main protease (Mpro) and TMPRSS2 protein. Both the viral protein and the host protein play an important role in the viral life cycle, such as post-translational modification and viral spike protein priming. This study has been performed by molecular docking of the compounds using PyRx with AutoDock Vina on the two aforementioned targets chosen for this study, i.e., SARS-CoV-2 Mpro and TMPRSS2. The compounds showed good binding affinity and are further analyzed by (Molecular dynamic) MD and Molecular Mechanics Poisson-Boltzmann Surface Area MM-PBSA study. The MD-simulation study has predicted that these natural compounds will have a great impact on the stabilization of the binding cavity of the Mpro of SARS-CoV-2. The predicted pharmacokinetic parameters also show that these compounds are expected to have good solubility and absorption properties. Further predictions for these compounds also showed no involvement in drug-drug interaction and no toxicity.Entities:
Keywords: MM-PBSA; SARS-CoV-2; molecular docking; molecular dynamic simulation; polyphenols
Mesh:
Substances:
Year: 2020 PMID: 33050360 PMCID: PMC7587198 DOI: 10.3390/molecules25204604
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1(A) Homology model of TMPRSS2, (B) predicted local quality estimation with chart of target by SWISS-Model server, and (C) sequence alignment between model target(TMPRSS2) and Human Hepsin TMPRSS1 (Human Hepsin TMPRSS1 (5ce1.1.A).1.A.
Figure 2Predicted 3D structure of the ligand-protein interaction at the left side and 2D animated pose showing interaction. (A) Main proteases protein of SARS-CoV-2 with glucogallin. (B) Main proteases protein of SARS-CoV-2 with mangiferin. (C) Main proteases protein of SARS-CoV-2 with phlorizin. (D) Main proteases protein of SARS-CoV-2 with N3. (E) Main proteases protein of SARS-CoV-2 with remdesivir. (F) Main proteases protein of SARS-CoV-2 with X77.
Predicted interactive residues of SARS-CoV-2 main protease with ligands.
| Compound | Number of Conventional H Bonding | Residue Receptor | Bond Length(Å) | Docking Score (kcal/mol) | Actual Residue by Experimental Crystal Structure | Ref. |
|---|---|---|---|---|---|---|
| Remdesivir | 5 | THR199(A), ASP289(A), LYS137(A), ARG 131(A), LEU287(A) | 2.51, 2.66, 2.91 2.75, 3.10 | −7.9 | - | - |
| N3 | 8 | HIS41(A), THR190(A), GLU166(A), GLN189(A), THR26(A), GLY143(A), CYS145(A) (2H bonding) | 2.65, 2.42, 2.65, 1.81, 3.10, 1.98, 3.40, 3.45 | −7.5 | GLN 189 (A),THR190(A),GLU166(A),PHE140(A),HIS164(A) and GLY 143(A) | [ |
| X77 | 5 | HIS164(A), GLY143(A), ASN142(A), GLU166(A), PHE140(A) | 2.35, 3.09, 2.05, 2.19, 2.73 | −8.6 | GLY143(A), GLU166(A), ASN142(A) and CYS145(A) | [ |
| Glucogallin | 6 | CYS145(A), SER144(A), GLY143(A) (2H bonding), HIS163(A), MET165(A) | 3.3, 2.37, 2.40, 1.97, 2.40, 3.05 | −7.0 | - | - |
| Mangiferin | 6 | LEU141(A), SER144(A), ASN142(A) (2H bonding),THR 190(A) (2H bonding) | 2.26,2.80, 2.72 2.12, 2.46,1.91 | −8.5 | - | - |
| Phlorizin | 6 | GLN189(A), MET49(A), CYS145(A), MET165(A), GLY143(A), SER144(A) | 2.25, 2.98,3.75,2.88,2.59, 2.73 | −7.9 | - | - |
Figure 3Predicted 3D structure of the ligand–protein interaction at the left side and 2D animated pose showing interaction. (A) TMPRSS2 protein of SARS-CoV-2 with mangiferin. (B) TMPRSS2 protein of SARS-CoV-2 with glucogallin. (C) TMPRSS2 protein of SARS-CoV-2 with phlorizin. (D) TMPRSS2 protein of SARS-CoV-2 with camostat mesylate.
Predicted interactive residues of TMPRSS2 with ligands.
| Compound | Number of H Bonding | Residue Receptor | Bond Length (Å) | Docking Score (kcal/mol) |
|---|---|---|---|---|
| Camostat mesylate | 4 | GLY464(A) (2H bonding), CYS465(A), HIS296(A), ASP 435(A) | 2.30, 2.37, 2.92, 2.58,2.14 | −7.1 |
| Glucogallin | 4 | SER441(A) (2H bonding), VAL280(A), GLY439(A), GLY 462(A) | 2.15, 2.19, 2.52, 2.75, 2.29 | −6.9 |
| Mangiferin | 2 | ALA 243(A), GLU 289(A) | 2.05, 2.07 | −6.9 |
| Phlorizin | 4 | SER460(A), SER441(A), GLY 464(A) (2H bonding) | 2.20, 2.64, 1.97, 2.59 | −7.7 |
Figure 4Target prediction, (A) remdesivir, (B) X77, (C) N3, (D) camostat mesylate, (E) mangiferin, (F) glucogallin, and (G) phlorizin.
Prediction of toxicity study of the ligands.
| Compound | Maximum Tolerated Dose(Human) (log mg/kg/day) | Oral Rat Acute Toxicity (LD50) (mol/kg) | Oral Rat Chronic Toxicity (LOAEL) (log mg/kg bw/day) | T.PyriformisToxicity (log ug/L) | Minnow Toxicity (log mM) | Ames Toxicity | Hepato-Toxicity | Skin Sensitivity | hERGI/II |
|---|---|---|---|---|---|---|---|---|---|
| Remdesivir | 0.15 | 2.043 | 1.639 | 0.285 | 0.291 | NO | YES | NO | NO/YES |
| X77 | 0.601 | 2.396 | 1.528 | 0.285 | 2.563 | YES | YES | NO | NO/YES |
| N3 | 0.305 | 2.344 | 3.084 | 0.287 | −2.205 | YES | YES | NO | NO/YES |
| Camostat mesylate | 0.133 | 2.319 | 2.81 | 0.285 | 0.524 | NO | NO | NO | NO |
| Mangiferin | 0.58 | 2.396 | 4.277 | 0.285 | 5.898 | NO | NO | NO | NO |
| Glucogallin | 0.238 | 2.314 | 3.112 | 0.285 | 6.151 | NO | NO | NO | NO |
| Phlorizin | 0.555 | 2.494 | 4.667 | 0.285 | 6.334 | NO | NO | NO | NO |
Figure 5(A) Docked phlorizin-Mpro complex (t = 0), (B) phlorizin-Mpro complex after MD (t = 10ns), (C) Docked glucogallin-Mpro complex (t = 0), (D) glucogallin-Mpro complex after MD (t = 10ns), (E) Docked mangiferin-Mpro complex (t = 0), (F) mangiferin-Mpro complex after MD (t = 10ns).
Figure 6(A) Docked phlorizin-TMPRSS2 complex (t = 0), (B) phlorizin-TMPRSS2 complex after MD (t = 10ns), (C) Docked glucogallin-TMPRSS2 complex (t = 0), (D) glucogallin-TMPRSS2 complex after MD (t = 10ns), (E) Docked mangiferin-TMPRSS2 complex (t = 0) and (F) mangiferin-TMPRSS2 complex after MD (t = 10ns).
Figure 7Hypothetical illustration of the anti-SARS-CoV-2 activity of the three polyphenolic compounds.
Predicted MM-PBSA analysis for calculation of thermodynamics parameters.
| Target-Ligand | Binding Energy | Solvation Energy | Electrostatic Energy | Van der WaalsEnergy | SASA Energy |
|---|---|---|---|---|---|
| Mpro-Remdesivir | −5.4127 ± 4.24 | 36.394 ± 8.92 | −12.87 ± 4.90 | −25.58 ± 5.40 | −3.342 ± 0.53 |
| Mpro-X77 | −14.16 ± 11.478 | 35.77 ± 20.88 | −9.35 ± 5.597 | −36.71 ± 19.14 | −3.879 ± 2.05 |
| Mpro-N3 | −16.58 ± 8.263 | 57.78 ± 26.110 | −18.49 ± 8.145 | −50.04 ± 20.54 | −5.834 ± 2.39 |
| CamostatMesylate-TMPRSS2 | −34.6558 ± 4.34 | −76.79 ± 16.5 | −53.95 ± 7.26 | −34.70 ± 4.34 | −4.349 ± 0.35 |
| Mpro-phlorizin | −9.65 ± 3.33 | 36.80 ± 6.52 | −10.1 ± 3.40 | −32.29 ± 5.15 | −4.02 ± 0.45 |
| Mpro-Glucogallin | −8.22 ± 2.52 | 34.190 ± 2.78 | −10.34 ± 6.28 | −29.56 ± 2.43 | −3.55 ± 0.25 |
| Mpro-Mangiferin | −4.50 ± 8.37 | 33.33 ± 23.71 | −6.419 ± 5.76 | −24.33 ± 12.7 | −3.15 ± 1.64 |
| TMPRSS2-Phlorizin | −1.57 ± 4.83 | 41.08 ± 9.90 | −11.67 ± 5.84 | −27.39 ± 5.29 | −3.59 ± 0.45 |
| TMPRSS2-Glucogallin | −1.10 ± 4.67 | 40.68 ± 7.25 | −15.63 ± 4.89 | −22.96 ± 3.52 | −3.18 ± 0.26 |
| TMPRSS2-Mangiferin | −3.04 ± 3.98 | 46.366 ± 10.41 | −19.34 ± 8.453 | −26.40 ± 3.01 | −3.65 ± 0.25 |